Loading...
Loading...
BCDA| Name | Value |
|---|---|
| Revenues | 0.1M |
| Cost of Revenue | 11.9M |
| Gross Profit | -11.8M |
| Operating Expense | 3.1M |
| Operating I/L | -3.0M |
| Other Income/Expense | -0.0M |
| Interest Income | 0.0M |
| Pretax | -3.0M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -3.0M |
BioCardia, Inc. is a clinical-stage regenerative medicine company specializing in the development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company's primary focus is on its lead therapeutic candidate, the CardiAMP Cell Therapy System, designed for the treatment of heart failure and chronic myocardial ischemia. Additionally, BioCardia is developing an allogeneic cell therapeutic platform, including investigational culture expanded bone marrow derived mesenchymal cell therapy, currently in Phase I/II trial for the treatment of ischemic systolic heart failure. The company also offers the Helix biotherapeutic delivery system and Morph deflectable guides and sheaths for delivering therapeutics into the heart muscle.
